Literature DB >> 28285330

Hepatitis B vaccination status in an at-risk adult population: long-term immunity but insufficient coverage.

S Hustache1, L Moyroud1,2, L Goirand1, O Epaulard3,4,5,6.   

Abstract

In France, hepatitis B (HB) vaccine has been offered to all infants since 1994, and was proposed to all children aged 11 years from 1994 to 1998. Nevertheless, HB vaccine hesitancy may result in low vaccination coverage in present-day at-risk adults. We aimed to determine HB vaccination coverage in adults attending a free testing center for sexually transmitted infections (STI). As part of routine care, three classes of data were anonymously collected from attendees over a 3-month period: results of HB serologic tests; date and number of past anti-hepatitis B virus (HBV) immunization(s) (if any) according to health records; and the risk of STI and blood-transmitted infections (BTI). The study included 735 participants (age 27.9 ± 9.2; 59.9% men). According to available health records (341 participants), 56.6% had received at least three and 67.2% at least one vaccine injection(s); 57.7% had received their last injection between 1994 and 1998, reflecting the strong vaccine policy during these years. Serologic testing (in 705 participants) showed evidence of a past or active HBV infection for 33 participants; of the remaining patients, 55.3% had anti-HBs antibody titers ≥10 IU/L. This rate was not higher in participants considered at risk for STI/BTI. Of the participants who received their last vaccine injection more than 15 years previously, 90.5% had anti-HBs antibody concentrations ≥10 and 60.3% ≥100 IU/mL. HB vaccination coverage is low in this population. Most of the vaccinated participants were immunized between 1994 and 1998, suggesting a failure of catch-up immunization of adolescents and at-risk adults. Long-term seroprotection persisted among vaccinated participants.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28285330     DOI: 10.1007/s10096-017-2957-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  22 in total

1.  No increase in demyelinating diseases after hepatitis B vaccination.

Authors:  F Zipp; J G Weil; K M Einhäupl
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

2.  Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents.

Authors:  Andrea Gabbuti; Luisa Romanò; Pierluigi Blanc; Francesca Meacci; Antonella Amendola; Alfonso Mele; Francesco Mazzotta; Alessandro R Zanetti
Journal:  Vaccine       Date:  2007-01-19       Impact factor: 3.641

3.  Knowledge, attitudes and vaccination coverage of healthcare workers regarding occupational vaccinations.

Authors:  P Loulergue; F Moulin; G Vidal-Trecan; Z Absi; C Demontpion; C Menager; M Gorodetsky; D Gendrel; L Guillevin; O Launay
Journal:  Vaccine       Date:  2009-04-07       Impact factor: 3.641

4.  A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen.

Authors:  Brenna C Simons; Philip R Spradling; Dana J T Bruden; Carolyn Zanis; Samantha Case; Tammy L Choromanski; Minjun Apodaca; Hazel D Brogdon; Gaelen Dwyer; Mary Snowball; Susan Negus; Michael G Bruce; Chihiro Morishima; Cindy Knall; Brian J McMahon
Journal:  J Infect Dis       Date:  2016-04-07       Impact factor: 5.226

5.  Targeted vaccination programme successful in reducing acute hepatitis B in men having sex with men in Amsterdam, the Netherlands.

Authors:  Gini van Rijckevorsel; Jane Whelan; Mirjam Kretzschmar; Evelien Siedenburg; Gerard Sonder; Ronald Geskus; Roel Coutinho; Anneke van den Hoek
Journal:  J Hepatol       Date:  2013-08-13       Impact factor: 25.083

6.  Vaccinations and risk of central nervous system demyelinating diseases in adults.

Authors:  Frank DeStefano; Thomas Verstraeten; Lisa A Jackson; Catherine A Okoro; Patti Benson; Steven B Black; Henry R Shinefield; John P Mullooly; William Likosky; Robert T Chen
Journal:  Arch Neurol       Date:  2003-04

Review 7.  Hepatitis B vaccination and French Society ten years after the suspension of the vaccination campaign: how should we raise infant immunization coverage rates?

Authors:  Marta A Balinska
Journal:  J Clin Virol       Date:  2009-08-28       Impact factor: 3.168

8.  Hepatitis vaccination and infection among gay, bisexual, and other men who have sex with men who attend gyms in New York City.

Authors:  Daniel E Siconolfi; Perry N Halkitis; Meighan E Rogers
Journal:  Am J Mens Health       Date:  2008-03-31

9.  Negative perceptions of hepatitis B vaccination among attendees of an urban free testing center for sexually transmitted infections in France.

Authors:  Lauranne Moyroud; Sarah Hustache; Laurence Goirand; Marianne Hauzanneau; Olivier Epaulard
Journal:  Hum Vaccin Immunother       Date:  2016-12-12       Impact factor: 3.452

10.  Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors.

Authors:  Christine Meffre; Yann Le Strat; Elisabeth Delarocque-Astagneau; Fréderic Dubois; Denise Antona; Jean-Marie Lemasson; Josiane Warszawski; Josiane Steinmetz; Dominique Coste; Jean-François Meyer; Sandrine Leiser; Jean-Pierre Giordanella; René Gueguen; Jean-Claude Desenclos
Journal:  J Med Virol       Date:  2010-04       Impact factor: 2.327

View more
  2 in total

1.  Trends in Hepatitis B Infection and Immunity Among Women of Childbearing Age in the United States.

Authors:  Tatyana Kushner; Zhen Chen; Stacy Tressler; Harvey Kaufman; Judith Feinberg; Norah A Terrault
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 9.079

2.  Knowledge, Attitudes, and Behaviors of Parents towards Recommended Adult Vaccinations: An Explanatory Survey in the Geographic Area of Naples, Italy.

Authors:  Francesco Napolitano; Giorgia Della Polla; Italo Francesco Angelillo
Journal:  Int J Environ Res Public Health       Date:  2019-06-12       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.